Every AI newsletter, investors ask questions on the investor interaction platform: Dear secretary, hello. Can the supply of covid-19 specific drug intermediates have an impact on the company’s performance
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) (300497. SZ) said on the investor interaction platform on January 23 that the current income of relevant intermediate products accounts for a relatively small proportion, which has not had a significant impact on the company’s performance. It is uncertain whether the company can form a long-term and stable cooperative relationship with customers in the future, and there is also uncertainty about the market demand of the drug.
